In MM.1S in vivo tumor models, BCMA CAR T cells significantly reduced flux and prolonged survival relative to Mock (untransduced) and tumor only controls, demonstrating tumor clearance that is in line with other clinically validated BCMA CARs...CD47 overexpressing BCMA CAR T cells expand and reduce tumor cell counts at low E:T ratios of 1:8 while uncontrolled tumor growth was observed in wells treated with the same total number of Mock, untransduced T cells.... Our BCMA CAR T cells control MM.1S tumor cells in vivo with efficacy on par to other clinically validated BCMA CARs. BCMA CAR T cells overexpressing CD47 exhibit superior in vitro efficacy against BCMA+ tumor cells compared to treatment with the same total number of Mock untransduced T cells.